Fumiaki Shiratori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fumiaki Shiratori has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Hideaki Shimada
Department of Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan
3 shared publications Hirotaka Takizawa
Port Square Kashiwado Clinic, Kashiwado Memorial Foundation Chiba Japan
2 shared publications- Makoto Sumazaki
Department of Clinical Oncology,Toho University Graduate School of Medicine,Tokyo,Japan, Japan
2 shared publications Satoshi Yajima
Department of Surgery, School of Medicine Toho University Tokyo Japan
2 shared publicationsTakashi Suzuki
Department of Surgery, School of Medicine Toho University Tokyo Japan
2 shared publicationsTomoo Matsutani
Department of Neurological Surgery Graduate School of Medicine, Chiba University Chiba Japan
2 shared publications
Latest Publications
- Open Access
- 16 January 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (4) , 658-667
Prognostic significance of six autoantibodies in esophageal squamous cell carcinoma: A prospective multi‐institutional study
Aim: Serum autoantibodies have been reported to react with tumor‐associated antigens in various cancers. This study evaluated the diagnostic and prognostic significance of six autoantibody panels in esophageal squamous cell carcinoma.Methods: In this study, 193 patients with esophageal squamous cell carcinoma and 78 healthy controls were enrolled. Serum antibodies were detected using originally developed enzyme‐linked immunosorbent assays to detect autoantibodies against the following tumor antigens: c‐myc, p62, RalA, p53, Sui1, and NY‐ESO‐1. The positive rates of the six‐autoantibody panel were compared with those of SCC antigen (SCC‐Ag). The prognostic significance of these autoantibodies was also evaluated.Results: The overall positive rate was significantly higher in the six‐autoantibody panel than in SCC‐Ag (72% vs. 28%; p < 0.01). The positive rates of the six‐autoantibody panel were 71% in stage 0/I, 73% in stage II, and 71% in stage III. No clinicopathological factors were associated with autoantibodies. Although the difference was not significant, the overall survival of the autoantibody‐positive group was worse than that of the autoantibody‐negative group (p = 0.14).Conclusion: The six‐autoantibody panel was useful for detecting esophageal squamous cell carcinoma, particularly in stage 0/I; however, it showed limited prognostic significance.
- 16 January 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (4) , 658-667
Open AccessPrognostic significance of six autoantibodies in esophageal squamous cell carcinoma: A prospective multi‐institutional study
Aim: Serum autoantibodies have been reported to react with tumor‐associated antigens in various cancers. This study evaluated the diagnostic and prognostic significance of six autoantibody panels in esophageal squamous cell carcinoma.Methods: In this study, 193 patients with esophageal squamous cell carcinoma and 78 healthy controls were enrolled. Serum antibodies were detected using originally developed enzyme‐linked immunosorbent assays to detect autoantibodies against the following tumor antigens: c‐myc, p62, RalA, p53, Sui1, and NY‐ESO‐1. The positive rates of the six‐autoantibody panel were compared with those of SCC antigen (SCC‐Ag). The prognostic significance of these autoantibodies was also evaluated.Results: The overall positive rate was significantly higher in the six‐autoantibody panel than in SCC‐Ag (72% vs. 28%; p < 0.01). The positive rates of the six‐autoantibody panel were 71% in stage 0/I, 73% in stage II, and 71% in stage III. No clinicopathological factors were associated with autoantibodies. Although the difference was not significant, the overall survival of the autoantibody‐positive group was worse than that of the autoantibody‐negative group (p = 0.14).Conclusion: The six‐autoantibody panel was useful for detecting esophageal squamous cell carcinoma, particularly in stage 0/I; however, it showed limited prognostic significance.
- Open Access
- 18 April 2024
- Published by Wiley in Cancer Science
- Vol. 115 (7) , 2209-2219
Combination of high anti‐SKI and low anti‐TMED5 antibody levels is preferable prognostic factor in esophageal carcinoma
Given that esophageal cancer is highly malignant, the discovery of novel prognostic markers is eagerly awaited. We performed serological identification of antigens by recombinant cDNA expression cloning (SEREX) and identified SKI proto‐oncogene protein and transmembrane p24 trafficking protein 5 (TMED5) as antigens recognized by serum IgG antibodies in patients with esophageal carcinoma. SKI and TMED5 proteins were expressed in Escherichia coli, purified by affinity chromatography, and used as antigens. The serum anti‐SKI antibody (s‐SKI‐Ab) and anti‐TMED5 antibody (s‐TMED5‐Ab) levels were significantly higher in 192 patients with esophageal carcinoma than in 96 healthy donors. The presence of s‐SKI‐Abs and s‐TMED5‐Abs in the patients' sera was confirmed by western blotting. Immunohistochemical staining showed that the TMED5 protein was highly expressed in the cytoplasm and nuclear compartments of the esophageal squamous cell carcinoma tissues, whereas the SKI protein was localized predominantly in the nuclei. Regarding the overall survival in 91 patients who underwent radical surgery, the s‐SKI‐Ab‐positive and s‐TMED5‐Ab‐negative statuses were significantly associated with a favorable prognosis. Additionally, the combination of s‐SKI‐Ab‐positive and s‐TMED5‐Ab‐negative cases showed an even clearer difference in overall survival as compared with that of s‐SKI‐Ab‐negative and s‐TMED5‐Ab‐positive cases. The s‐SKI‐Ab and s‐TMED5‐Ab biomarkers are useful for diagnosing esophageal carcinoma and distinguishing between favorable and poor prognoses.
- 18 April 2024
- Published by Wiley in Cancer Science
- Vol. 115 (7) , 2209-2219
Open AccessCombination of high anti‐SKI and low anti‐TMED5 antibody levels is preferable prognostic factor in esophageal carcinoma
Given that esophageal cancer is highly malignant, the discovery of novel prognostic markers is eagerly awaited. We performed serological identification of antigens by recombinant cDNA expression cloning (SEREX) and identified SKI proto‐oncogene protein and transmembrane p24 trafficking protein 5 (TMED5) as antigens recognized by serum IgG antibodies in patients with esophageal carcinoma. SKI and TMED5 proteins were expressed in Escherichia coli, purified by affinity chromatography, and used as antigens. The serum anti‐SKI antibody (s‐SKI‐Ab) and anti‐TMED5 antibody (s‐TMED5‐Ab) levels were significantly higher in 192 patients with esophageal carcinoma than in 96 healthy donors. The presence of s‐SKI‐Abs and s‐TMED5‐Abs in the patients' sera was confirmed by western blotting. Immunohistochemical staining showed that the TMED5 protein was highly expressed in the cytoplasm and nuclear compartments of the esophageal squamous cell carcinoma tissues, whereas the SKI protein was localized predominantly in the nuclei. Regarding the overall survival in 91 patients who underwent radical surgery, the s‐SKI‐Ab‐positive and s‐TMED5‐Ab‐negative statuses were significantly associated with a favorable prognosis. Additionally, the combination of s‐SKI‐Ab‐positive and s‐TMED5‐Ab‐negative cases showed an even clearer difference in overall survival as compared with that of s‐SKI‐Ab‐negative and s‐TMED5‐Ab‐positive cases. The s‐SKI‐Ab and s‐TMED5‐Ab biomarkers are useful for diagnosing esophageal carcinoma and distinguishing between favorable and poor prognoses.
- Open Access
- 16 September 2020
- Published by Wiley in Cancer Science
- Vol. 111 (12) , 4453-4464
Serum anti‐LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases
Some cancers are related to atherosclerotic diseases; therefore, these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening of sera was performed from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay‐linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione donor beads and anti‐human IgG acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low‐density lipoprotein receptor–related protein–associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S‐transferase–fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis‐related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well‐known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.
- 16 September 2020
- Published by Wiley in Cancer Science
- Vol. 111 (12) , 4453-4464
Open AccessSerum anti‐LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases
Some cancers are related to atherosclerotic diseases; therefore, these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening of sera was performed from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay‐linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione donor beads and anti‐human IgG acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low‐density lipoprotein receptor–related protein–associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S‐transferase–fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis‐related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well‐known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.